Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICL670 vs placebo in low-/int-1-risk MDS with iron overload
CTR20130862Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Novartis. Started Jan 2015; status: completed.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20130862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130862.